91 related articles for article (PubMed ID: 1437753)
1. [Activity of natural cytotoxic cells in non-Hodgkin's lymphoma].
Frydecka I; Kotlarek-Haus S; Kuliczkowski K; Kuliszkiewicz-Janus M
Pol Tyg Lek; 1992 Apr 20-27; 47(16-17):357-9. PubMed ID: 1437753
[TBL] [Abstract][Full Text] [Related]
2. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Scheid C; Pettengell R; Ghielmini M; Radford JA; Morgenstern GR; Stern PL; Crowther D
Bone Marrow Transplant; 1995 Jun; 15(6):901-6. PubMed ID: 7581089
[TBL] [Abstract][Full Text] [Related]
3. Natural killer activity and NK cytotoxic factors in peripheral blood and lymph node cells from non-Hodgkin's lymphoma patients.
Nadkarni JJ; Mehta BA; Koppikar SB; Soman CS; Shrikhande SS; Advani SH
Neoplasma; 1989; 36(6):701-8. PubMed ID: 2615873
[TBL] [Abstract][Full Text] [Related]
4. Natural killer (NK) activity in patients with Hodgkin's disease before, during and after multiple-agent therapy.
Frydecka I; Kotlarek-Haus S; Kuliszkiewicz-Janus M; Kuliczkowski K
Arch Immunol Ther Exp (Warsz); 1990; 38(5-6):407-14. PubMed ID: 2130805
[TBL] [Abstract][Full Text] [Related]
5. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
6. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
7. Natural killer activity and antibody-dependent cellular cytotoxicity in patients with non-Hodgkin's lymphoma.
Metha BA; Advani SH; Nadkarni SJ
Neoplasma; 1988; 35(1):61-8. PubMed ID: 3352838
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
9. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
Almici C; Manoni L; Carlo-Stella C; Garau D; Cottafavi L; Rizzoli V
Bone Marrow Transplant; 1995 Jul; 16(1):95-101. PubMed ID: 7581136
[TBL] [Abstract][Full Text] [Related]
10. Increased number of functionally defective large granular lymphocytes in lymphoma patients.
Muhonen T; Teerenhovi L; Saksela E
Nat Immun Cell Growth Regul; 1987; 6(2):57-64. PubMed ID: 3600676
[TBL] [Abstract][Full Text] [Related]
11. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
[TBL] [Abstract][Full Text] [Related]
12. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
13. [The grouping of morphological variants of non-Hodgkin's lymphomas (lymphosarcomas) by the degree of malignancy].
Sotnikov VM; Kharchenko VP; Pan'shin GA; Galil-Ogly GA; Zakharova LV; Teĭblium MM
Klin Med (Mosk); 1996; 74(2):41-3. PubMed ID: 8772102
[TBL] [Abstract][Full Text] [Related]
14. Natural killer cell activity in families of patients with systemic lupus erythematosus: demonstration of a killing defect in patients.
Green MR; Kennell AS; Larche MJ; Seifert MH; Isenberg DA; Salaman MR
Clin Exp Immunol; 2005 Jul; 141(1):165-73. PubMed ID: 15958083
[TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics and treatment of midline nasal and nasal type NK/T cell lymphoma].
Yong W; Zheng W; Zhang Y
Zhonghua Yi Xue Za Zhi; 2001 Jul; 81(13):773-5. PubMed ID: 11798962
[TBL] [Abstract][Full Text] [Related]
16. Normal natural killer cell activity in Hodgkin's disease patients in remission.
Douer D; Shaked N; Ramot B
Clin Exp Immunol; 1987 Sep; 69(3):660-7. PubMed ID: 3665188
[TBL] [Abstract][Full Text] [Related]
17. Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease.
Jezewska E; Björkholm M; Giscombe R; Holm G; Tullgren O
Clin Exp Immunol; 1985 Jul; 61(1):96-102. PubMed ID: 4042422
[TBL] [Abstract][Full Text] [Related]
18. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
19. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
[TBL] [Abstract][Full Text] [Related]
20. Intracellular IL-4/IFN-gamma producing peripheral T lymphocyte subsets in B cell non-Hodgkin's lymphoma patients.
Gergely L; Aleksza M; Váróczy L; Ponyi A; Sipka S; Illés A; Szegedi G
Eur J Haematol; 2004 May; 72(5):336-41. PubMed ID: 15059068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
